Total Payments
$944,765
2024 Payments
$215,345
Companies
19
Transactions
1,045
Medicare Patients
680
Medicare Billing
$88,387
Payment Breakdown by Category
Other$691,878 (73.2%)
Consulting$138,397 (14.6%)
Travel$92,558 (9.8%)
Food & Beverage$20,003 (2.1%)
Research$1,088 (0.1%)
Education$840.94 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $689,078 | 258 | 72.9% |
| Consulting Fee | $138,397 | 50 | 14.6% |
| Travel and Lodging | $92,558 | 360 | 9.8% |
| Food and Beverage | $20,003 | 349 | 2.1% |
| Grant | $2,000 | 1 | 0.2% |
| Unspecified | $1,088 | 13 | 0.1% |
| Education | $840.94 | 13 | 0.1% |
| Honoraria | $800.00 | 1 | 0.1% |
Payments by Type
General
$943,677
1,032 transactions
Research
$1,088
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $278,463 | 279 | $0 (2024) |
| Biogen, Inc. | $150,577 | 225 | $0 (2024) |
| Genentech USA, Inc. | $148,652 | 128 | $0 (2024) |
| GENZYME CORPORATION | $108,557 | 110 | $0 (2024) |
| TG Therapeutics, Inc. | $89,438 | 83 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $54,052 | 58 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $29,940 | 40 | $0 (2019) |
| Celgene Corporation | $28,409 | 43 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $19,798 | 16 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $15,264 | 14 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $215,345 | 183 | EMD Serono, Inc. ($133,470) |
| 2023 | $138,274 | 137 | EMD Serono, Inc. ($56,565) |
| 2022 | $67,977 | 80 | EMD Serono, Inc. ($16,152) |
| 2021 | $40,585 | 37 | Genentech USA, Inc. ($9,565) |
| 2020 | $60,261 | 76 | Biogen, Inc. ($23,764) |
| 2019 | $120,831 | 168 | GENZYME CORPORATION ($39,092) |
| 2018 | $142,409 | 171 | Genentech USA, Inc. ($42,918) |
| 2017 | $159,084 | 193 | Biogen, Inc. ($38,375) |
All Payment Transactions
1,045 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,488.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,653.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $817.58 | General |
| Category: Neurology | ||||||
| 12/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $481.20 | General |
| Category: Neurology | ||||||
| 12/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $200.91 | General |
| Category: Neurology | ||||||
| 12/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $153.29 | General |
| Category: Neurology | ||||||
| 12/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $136.61 | General |
| Category: Neurology | ||||||
| 12/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.94 | General |
| 12/18/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,347.00 | General |
| Category: Neurology | ||||||
| 12/11/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,273.00 | General |
| Category: Neurology | ||||||
| 12/09/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,843.00 | General |
| 12/09/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,463.00 | General |
| 12/08/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 12/08/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $146.06 | General |
| Category: Immunology | ||||||
| 12/08/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Immunology | ||||||
| 12/08/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | Cash or cash equivalent | $9.77 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,443.00 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,488.00 | General |
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $68.56 | General |
| Category: Neurology | ||||||
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Neurology | ||||||
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $27.49 | General |
| Category: Neurology | ||||||
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $18.76 | General |
| Category: Neurology | ||||||
| 12/02/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,653.00 | General |
| Category: Neurology | ||||||
| 11/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,843.00 | General |
| Category: Neurology | ||||||
| 11/19/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,347.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M14-397 | AbbVie, Inc. | $1,072 | 12 |
| An Observational, Prospective Study Evaluating Persistence on Treatment, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World Setting | Biogen, Inc. | $16.35 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 146 | 192 | $105,396 | $20,218 |
| 2022 | 4 | 175 | 220 | $111,971 | $22,970 |
| 2021 | 3 | 172 | 229 | $122,771 | $25,253 |
| 2020 | 4 | 187 | 233 | $87,783 | $19,947 |
Total Patients
680
Total Services
874
Medicare Billing
$88,387
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 97 | 135 | $81,000 | $15,810 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 57 | $24,396 | $4,408 | 18.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 109 | 151 | $90,298 | $18,523 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 40 | $16,960 | $3,693 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 13 | $3,913 | $579.28 | 14.8% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Office | 2022 | 15 | 16 | $800.00 | $174.22 | 21.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 107 | 152 | $91,504 | $19,363 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 62 | $26,722 | $4,895 | 18.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 15 | $4,545 | $994.84 | 21.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 74 | 103 | $47,792 | $9,890 | 20.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 66 | 78 | $26,988 | $6,147 | 22.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 31 | 35 | $10,157 | $3,123 | 30.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 16 | 17 | $2,846 | $787.15 | 27.7% |
About Dr. Kyle Smoot, M.D
Dr. Kyle Smoot, M.D is a Neurology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1124170063.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kyle Smoot, M.D has received a total of $944,765 in payments from pharmaceutical and medical device companies, with $215,345 received in 2024. These payments were reported across 1,045 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($689,078).
As a Medicare-enrolled provider, Smoot has provided services to 680 Medicare beneficiaries, totaling 874 services with total Medicare billing of $88,387. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Portland, OR
- Active Since 01/18/2007
- Last Updated 11/30/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1124170063
Products in Payments
- Mavenclad (Drug) $122,341
- AUBAGIO (Drug) $102,782
- OCREVUS (Biological) $88,078
- BRIUMVI (Drug) $84,057
- TECFIDERA (Drug) $52,145
- TYSABRI (Biological) $36,036
- Rebif (Biological) $33,903
- ZEPOSIA (Drug) $32,609
- Non-Covered Product (Drug) $31,721
- Ocrevus (Biological) $30,538
- GILENYA (Drug) $30,290
- COPAXONE (Drug) $29,492
- MAVENCLAD (Drug) $25,770
- VUMERITY (Drug) $24,980
- Mavenclad (Biological) $22,885
- Ponvory (Drug) $10,142
- Evobrutinib $9,600
- AMPYRA (Drug) $9,444
- KESIMPTA (Drug) $7,512
- Ozanimod (Drug) $6,833
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Portland
Stanley Cohan, M.d, M.D
Neurology — Payments: $664,935
Neurology $664,935
Dr. Chafic Karam, M.d, M.D
Neurology — Payments: $647,064
Neurology $647,064
Dr. John Dolan, D.o, D.O
Neurology — Payments: $550,588
Neurology $550,588
Kiren Kresa-Reahl, M.d, M.D
Neurology — Payments: $421,575
Neurology $421,575
Matthew Brodsky, Md, MD
Neurology — Payments: $244,252
Neurology $244,252
David Spencer, Md, MD
Neurology — Payments: $101,259
Neurology $101,259